Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TarIFNiRA: anifrolumab in rheumatoid arthritis with high type I interferon signature
2017-001717-92Phase 2Terminated
- Sponsor
- Medical University of Vienna
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Anifrolumab with Placebo (2 arms). Primary endpoint: ACR20 response at week 24. Started Aug 2017; status: terminated.
02
Drugs
anifrolumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2017-001717-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001717-92.